Artwork

Innhold levert av The Johns Hopkins Bloomberg School of Public Health. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Johns Hopkins Bloomberg School of Public Health eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

812 - The Potentially “Game-changing” RSV Products Available This Season

13:40
 
Del
 

Manage episode 446471204 series 2635898
Innhold levert av The Johns Hopkins Bloomberg School of Public Health. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Johns Hopkins Bloomberg School of Public Health eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
About this episode:

Respiratory syncytial virus can be particularly dangerous for older adults and infants and this year, for the first time, there are three approved and readily available products to help prevent severe disease: A vaccine for pregnant women and people over age 65, and an antibody treatment for infants born during RSV season. In this episode: all about these products and they promise they show for dramatically reducing the number of hospitalizations and deaths from RSV this year.

Guests:

Dr. Georgina Peacock is the director of the Immunization Services Division in the National Center on Immunization and Respiratory Diseases at the CDC.

Host:

Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland’s Health Department.

Show links and related content: Contact us:

Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.

Follow us:
  continue reading

782 episoder

Artwork
iconDel
 
Manage episode 446471204 series 2635898
Innhold levert av The Johns Hopkins Bloomberg School of Public Health. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Johns Hopkins Bloomberg School of Public Health eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
About this episode:

Respiratory syncytial virus can be particularly dangerous for older adults and infants and this year, for the first time, there are three approved and readily available products to help prevent severe disease: A vaccine for pregnant women and people over age 65, and an antibody treatment for infants born during RSV season. In this episode: all about these products and they promise they show for dramatically reducing the number of hospitalizations and deaths from RSV this year.

Guests:

Dr. Georgina Peacock is the director of the Immunization Services Division in the National Center on Immunization and Respiratory Diseases at the CDC.

Host:

Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland’s Health Department.

Show links and related content: Contact us:

Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.

Follow us:
  continue reading

782 episoder

Tous les épisodes

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett